Peptide Reference
FOXO4-DRI
FOXO4-Derived Retro-Inverso Peptide
A synthetic peptide designed to induce apoptosis in senescent (aging) cells. Represents a new class of 'senolytic' therapies aimed at extending healthspan.
Status
research
Category
anti aging
Typical cost
$200-500/vial (10mg)
Mechanism
Disrupts the interaction between FOXO4 and p53 in senescent cells, causing targeted cell death of aging cells without harming healthy cells. Reduces systemic inflammation and improves tissue function.
Potential benefits
- Clearance of senescent cells
- Reduced inflammation
- Improved tissue function
- Potential lifespan extension
- Better kidney function (in studies)
Reported side effects
- Unknown long-term effects
- Immune activation concerns
- Injection site reactions
Common dosing references
subcutaneous
5-10mg · Intermittent (1-2x per month)
Ongoing research
Research notes
FOXO4-DRI in aged mice
2017
Restored physical fitness, hair density, and kidney function in aged mice by clearing senescent cells
Regulatory and sourcing notes
Experimental research chemical. Early stage. Not FDA-approved. Limited to animal studies and early human trials.
Cutting-edge research peptide. Extremely limited availability. Very early stage.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.